Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

US5728686A · kind A · utility

Assignee

• Hoechst GmbH · DE

Inventors

• Gunter Billen · Niedernhausen, DE
• Ismahan Okyayuz-Baklouti · Wiesbaden, DE
• Hiristo Anagnostopulos · Wiesbaden, DE
• Stefan Mullner · Langenfeld, DE

Key dates

• Filing date: Oct 31, 1996
• Grant date: Mar 17, 1998
• Expiry date: Oct 31, 2016

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula ##STR1## where R.sup.1 and R.sup.3 are identical or different and at least one of the radicals R.sup.1 and R.sup.3 is a radical of the formula XI ##STR2## in which E is a covalent bond or a (C.sub.1 -C.sub.5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.